C-reactive protein, inflammation, and coronary risk

Abstract

Data have revealed interactions between baseline concentration of hs-CRP and the efficacy of common pharmacologic therapies in primary and secondary prevention, suggesting not only that it may be possible to modify the increased risk associated with elevated hs-CRP, but also that inflammatory markers may be useful in targeting preventive therapies. Inflammatory markers may become a valuable component of routine cardiovascular risk assessment.